We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals

204 hedge funds and large institutions have $3.91B invested in Ionis Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 61 increasing their positions, 75 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

254% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 13

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

38% more capital invested

Capital invested by funds: $2.84B → $3.91B (+$1.07B)

18% more funds holding

Funds holding: 173204 (+31)

19% less repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 75

31% less call options, than puts

Call options by funds: $40.4M | Put options by funds: $58.5M

Holders
204
Holders Change
+31
Holders Change %
+17.92%
% of All Funds
6.61%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.16%
New
46
Increased
61
Reduced
75
Closed
13
Calls
$40.4M
Puts
$58.5M
Net Calls
-$18M
Net Calls Change
-$24.6M
Name Holding Trade Value Shares
Change
Change in
Stake
PCM
101
Perkins Capital Management
Minnesota
$1.98M -$415K -13,900 -21%
USAA
102
United Services Automobile Association
Texas
$1.97M -$2.99K -100 -0.2%
ACM
103
Avalon Capital Management
California
$1.91M +$644K +21,568 +73%
MOACM
104
Mutual of America Capital Management
New York
$1.69M +$1.34M +44,900 New
Citigroup
105
Citigroup
New York
$1.68M +$666K +22,300 +100%
PPA
106
Parametric Portfolio Associates
Washington
$1.57M -$354K -11,838 -22%
BNP Paribas Financial Markets
107
BNP Paribas Financial Markets
France
$1.47M -$29.9M -1,000,448 -96%
Capital Fund Management (CFM)
108
Capital Fund Management (CFM)
France
$1.43M -$3.66M -122,362 -76%
Principal Financial Group
109
Principal Financial Group
Iowa
$1.33M -$58.9K -1,972 -5%
Natixis Advisors
110
Natixis Advisors
Massachusetts
$1.29M -$245K -8,200 -19%
Public Employees Retirement Association of Colorado
111
Public Employees Retirement Association of Colorado
Colorado
$1.24M
PAM
112
Paradigm Asset Management
New York
$1.23M -$44.8K -1,500 -4%
DC
113
Davenport & Co
Virginia
$1.21M -$2.99K -100 -0.3%
SO
114
STRS Ohio
Ohio
$1.21M +$281K +9,400 +41%
Neuberger Berman Group
115
Neuberger Berman Group
New York
$1.19M -$46K -1,541 -5%
PI
116
Putnam Investments
Massachusetts
$1.19M +$303K +10,131 +47%
PP
117
Paloma Partners
Connecticut
$1.18M -$6.99K -234 -0.7%
Royal Bank of Canada
118
Royal Bank of Canada
Ontario, Canada
$1.12M +$192K +6,418 +27%
PNC Financial Services Group
119
PNC Financial Services Group
Pennsylvania
$1.09M +$304K +10,188 +54%
HI
120
HBK Investments
Texas
$1.01M +$801K +26,799 New
FC
121
FIC Capital
New York
$995K +$54.5K +1,825 +7%
GC
122
Globeflex Capital
California
$964K
RFC
123
Russell Frank Company
Washington
$938K -$82.3K -2,754 -10%
NCA
124
NCM Capital Advisers
North Carolina
$937K +$745K +24,950 New
T
125
TradeWorx
New Jersey
$934K -$921K -30,843 -55%

IONS Hedge Fund Activity: Q3 2013 in Review

204 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2013, worth a combined $3.91B — up 38% from $2.84B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new IONS positions and 13 closed out — a net gain of 33 holders — while 61 added to existing stakes and 75 trimmed.

The largest buyer was Artisan Partners, adding an estimated $43.9M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $29.9M.

  • 204 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2013, up from 173 in Q2 2013.
  • Funds reported $3.91B of Ionis Pharmaceuticals stock for Q3 2013, up 38% quarter-over-quarter.
  • 46 funds opened new Ionis Pharmaceuticals positions in Q3 2013 and 13 closed out, a net change of +33 holders.
  • The largest Ionis Pharmaceuticals buyer in Q3 2013 was Artisan Partners, an estimated $43.9M added.
  • The largest Ionis Pharmaceuticals seller in Q3 2013 was BNP Paribas Financial Markets, an estimated $29.9M sold.

Based on aggregated 13F filings for Q3 2013.